Ad
related to: biomarin pharmaceutical stock price forecast
Search results
Results from the WOW.Com Content Network
The stock of Biomarin Pharmaceutical (NAS:BMRN, 30-year Financials) gives every indication of being modestly undervalued, according to GuruFocus Value calculation.
The stock of Biomarin Pharmaceutical (NAS:BMRN, 30-year Financials) appears to be modestly undervalued, according to GuruFocus Value calculation.
For premium support please call: 800-290-4726 more ways to reach us
BioMarin markets a phosphate salt of 3,4-DAP under the name Firdapse. In 2010, BioMarin was granted exclusive licensing rights to Firdapse for 10 years. As a result, the price of a prescribed National Health Service treatment course has increased from $1,987 for the unlicensed drug to $69,970 for Firdapse. The company states that prior to its ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
For premium support please call: 800-290-4726 more ways to reach us
The NASDAQ Biotechnology Index is a stock market index made up of securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either the Biotechnology or the Pharmaceutical industry. [1] A list of the 225 components of the index is published online.
BioMarin Pharmaceutical Inc’s (NASDAQ:BMRN): BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare ...
Ad
related to: biomarin pharmaceutical stock price forecast